International Journal of Hyperthermia Impact Factor & Information

Publisher: European Society for Hyperthermic Oncology; North American Hyperthermia Group, Informa Healthcare

Journal description

The official journal of the North American Hyperthermia Society, the European Society for Hyperthermic Oncology, and the Japanese Society of Hyperthermic Oncology, the International Journal of Hyperthermia provides a forum for the publication of research and clinical studies and trials on hyperthermia which fall largely into the three main categories of clinical studies, biological studies and techniques of heat delivery and temperature measurement.

Current impact factor: 2.77

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.769
2012 Impact Factor 2.591
2011 Impact Factor 1.923
2010 Impact Factor 2.929
2009 Impact Factor 2.412
2008 Impact Factor 2.339
2007 Impact Factor 2.713
2006 Impact Factor 1.866
2005 Impact Factor 1.74
2004 Impact Factor 1.888
2003 Impact Factor 1.762
2002 Impact Factor 1.841
2001 Impact Factor 1.086
2000 Impact Factor 0.952
1999 Impact Factor 1.196
1998 Impact Factor 1.131
1997 Impact Factor 1.063
1996 Impact Factor 1.028
1995 Impact Factor 1.163
1994 Impact Factor 0.938
1993 Impact Factor 0.692
1992 Impact Factor 1.131

Impact factor over time

Impact factor

Additional details

5-year impact 2.73
Cited half-life 6.70
Immediacy index 0.48
Eigenfactor 0.00
Article influence 0.59
Website International Journal of Hyperthermia website
Other titles International journal of hyperthermia
ISSN 1464-5157
OCLC 53400193
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • On a non-profit server
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper compares the results obtained with numerical simulations and ex vivo experiments involving a dual applicator microwave thermal ablation system operating at a 2.45 GHz frequency, both in synchronous and asynchronous modes. Our purpose was to demonstrate that at this frequency an asynchronous or switched-mode system performs essentially as well as the synchronous one, in spite of the prevailing belief that coherence would assure better thermal (TH) synergy. Numerical analysis: The calculations of temperature fields were based on the Pennes bioheat equation, taking into account the effects of blood perfusion by means of a full-wave 3D simulator that allows numerical electromagnetic (EM) and TH analyses. Experiments were done using a 100 W microwave (MW) power generator and a fast switched-mode sequential 'active' power splitter. By adding a further passive power splitter we arranged a test bed for an accurate experimental comparison of synchronous versus switched-mode TH ablations. The experimental ablation zones produced by a dual applicator array on ex vivo swine tissue corresponded well with the simulated ones, confirming that the simplifications assumed in the full-wave analysis were compatible with the aim of our work. Numerical simulations and experiments show that at a 2.45 GHz industrial, scientific and medical (ISM) frequency, synchronous, asynchronous and switched-mode multi-probe systems are substantially equivalent in terms of ablative performance. Moreover, the switched-mode solution offers simpler operation along with lesser sensitivity to the placement of applicators in the tissue.
    International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1032369
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microwave ablation (MWA) is a new minimally invasive method for thermal ablation of benign thyroid nodules with promising results. The aim of this study was to investigate whether MWA has an impact on thyroid function. Thirty patients with a total of 34 benign thyroid nodules underwent MWA between January 2013 and July 2014. Serum levels of triiodothyronine (T3), thyroxine (T4), thyrotropin (TSH), thyroglobuline (Tg) and additionally antibodies against Tg (anti-Tg), thyrotropin receptors (TRAb) and thyroid peroxidase (anti-TPO) were measured at enrolment, 24 h after MWA, as well as at the 3-month and 6-month follow-up. Moreover, the nodule volume was evaluated to determine effectiveness. Serum TSH, T4, T3 and Tg levels did not change significantly at the 3-month or 6-month follow-up (p > 0.05); thyroid function was not affected by MWA. Antibody levels did not change significantly either; however, two patients developed antibodies after treatment. A volume reduction of 51.4% or 7.85 mL could be demonstrated after 3 months and a reduction of 55.8% or 14.0 mL after 6 months. Slight complications such as mild pain during the ablation or superficial haematomas emerged. The development of Graves' disease and mild Horner's syndrome were observed as more severe side effects. The data suggest MWA as an alternative for the treatment of benign thyroid nodules. While first results for preservation of thyroid function are positive, further measurements of laboratory data and especially antibodies are necessary.
    International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1032371
  • [Show abstract] [Hide abstract]
    ABSTRACT: The response of tissues to radiation with mild temperature hyperthermia is dependent on the interval between the two modalities. This study investigated the effect that the vascular disrupting agent OXi4503 had on this time-interval interaction. The normal right rear foot of female CDF1 mice or foot-implanted C3H mammary carcinomas were locally irradiated (230 kV X-rays) and heated (41.5 °C for 60 min) by foot immersion in a water bath. OXi4503 (50 mg/kg) was injected intraperitoneally 1.5 h before irradiating. Irradiation was performed either in the middle of the heating period (simultaneous treatment) or at 1 or 4 h prior to starting the heating (sequential treatments). Response was the percentage of mice showing local tumour control at 90 days or skin moist desquamation between days 11-23. From the radiation dose response curves the dose producing tumour control (TCD50) or moist desquamation (MDD50) in 50% of mice was calculated. The TCD50 and MDD50 values for radiation alone were 54 Gy and 29 Gy, respectively. Simultaneously heating the tissues enhanced radiation response, the respective TCD50 and MDD50 values being significantly (chi-square test, p < 0.05) reduced to 33 Gy and 14 Gy. A smaller enhancement was obtained with a sequential treatment in both tissues. OXi4503 enhanced the radiation response of tumour and skin. Combined with radiation and heat, the only effect was in tumours where OXi4503 prevented the decrease in sensitisation seen with the sequential treatment. Combining OXi4503 with a sequential radiation and heat treatment resulted in a 1.4-fold therapeutic gain.
    International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1024289
  • [Show abstract] [Hide abstract]
    ABSTRACT: The radioprotectors currently available are generally poorly tolerated in human beings; thus, their use has been restricted due to their side effects and their limited clinical tolerance. In a search for fewerand/or without side effects agents, the radioprotective effects of partial body hyperthermia (PBH) were tested on Wistar rats of both sexes at different ages. PBH (43 °C, 1 h) was carried out by immersion of each animal's lower parts and legs in a thermostatically controlled water bath 20 h prior to irradiation with a lethal single exposure dose of 9 Gy of gamma irradiation. Irradiated PBH pretreated animals were monitored for 30 days post-irradiation and survival percentages were calculated. The data obtained provide evidence that PBH treatment prolonged the irradiated rats' lifespans and the mortality rates varied significantly with animal age and sex. In addition, PBH treatment significantly enhanced bone marrow recovery of irradiated rats of both genders. Partial body hyperthermia prior to radiation proved to have beneficial effects on gamma irradiated rats.
    International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1026414
  • International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1033482
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this prospective preliminary study we evaluated changes of prostate volume and changes of brachytherapy treatment plan parameters due to interstitial hyperthermia (IHT) applied prior to high-dose-rate brachytherapy (HDRBT), compared to our standard HDRBT procedure. In a group of 60 consecutive patients with prostate adenocarcinoma, 30 were treated with HDRBT alone and 30 with IHT preceding HDRBT. Prior to catheter implantation, a 'virtual' treatment plan (VP) was complied, a 'live' plan (LP) was prepared before patient irradiation, and a 'post' plan (PP) was drawn up after completing the irradiation procedure. In each plan, based on transrectal ultrasound images, the contours of the prostate, urethra, and rectum were delineated and the respective volumes and dose-volume histogram parameters were evaluated. These parameters, established for the LP, were then compared with those of the PP. Changes in prostate volume and in parameters of the treatment plans were observed, but differences between the two patient groups were not statistically significant. For all 60 patients treated, the average prostate volume in the VP was 32 cm(3), in the LP 41 cm(3), and the PP 43 cm(3). Average values of relative changes in the therapy planning parameters between LP and PP were for the prostate D90 -5.7%, V100 -5.6%, V200 -13.2%, for the urethra D0, 1 cm(3) -1.6%, and for rectum D2 cm(3) 0%. Hyperthermia prior to HDRBT does not significantly change the volume of the prostate and there is no need to perform the new treatment plan after the hyperthermia session.
    International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1033481
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes the development of a new type of electromagnetic hyperthermia applicator delivering dose control within large application fields and increased effectiveness by providing simultaneous action of radiation and heating (SRH) in malignant tumours, and development of a dosimetric feedback method to support SRH. Single and phased arrays of flexible applicators have been developed to allow simultaneous hyperthermia and external beam therapy. A frequency of 434 MHz is used to heat near-surface and moderately deep-seated tumours and 70 MHz for deep-seated tumours. Phase and amplitude control allows focusing of electromagnetic energy (EM) to deep-seated tumours. The specific absorption rate (SAR) dose distribution can be modified to achieve uniform heating of tumours with complex shapes and heterogeneous tissue properties. A lithium fluoride thermoluminescent dosimeter (TLD) in a flexible film cassette has been developed for real-time dose measurement. Four types of 434 MHz applicators were manufactured with 3, 4, 9 or 12 independent applicators. Two types of 70 MHz applicators were made with 4 or 6 independent applicators. Phantom tests demonstrated the ability to control the SAR pattern by phase and amplitude control. Placement of the dosimeter between bolus and phantom increased the phantom surface temperature up to 3 °C and showed that the ratio of absorbed energy in TLD to dose in water approaches (0.83 ± 3%) for photon energies >60 keV. Simultaneous and controlled radiation and local hyperthermia is technically feasible in a preclinical setting, a clinical feasibility test is the next step.
    International Journal of Hyperthermia 04/2015; DOI:10.3109/02656736.2015.1026413
  • [Show abstract] [Hide abstract]
    ABSTRACT: Catheter-based ultrasound (CBUS) is applied to deliver minimally invasive thermal therapy to solid cancer tumours, benign tissue growth, vascular disease, and tissue remodelling. Compared to other energy modalities used in catheter-based surgical interventions, unique features of ultrasound result in conformable and precise energy delivery with high selectivity, fast treatment times, and larger treatment volumes. We present a concise review of CBUS technology being currently utilized in animal and clinical studies or being developed for future applications. CBUS devices have been categorised into interstitial, endoluminal and endovascular/cardiac applications. Basic applicator designs, site-specific evaluations and possible treatment applications have been discussed in brief. Particular emphasis has been given to ablation studies that incorporate image guidance for applicator placement, therapy monitoring, feedback control, and post-procedure assessment. Examples of devices included here span the entire spectrum of the development cycle from preliminary simulation-based design studies to implementation in clinical investigations. The use of CBUS under image guidance has the potential for significantly improving precision and applicability of thermal therapy delivery.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2015.1006269
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the safety and efficiency of ultrasound-guided percutaneous microwave (MW) ablation for the control of locally recurrent papillary thyroid carcinoma (LR-PTC) in patients for whom surgery is not viable. The inclusion criteria for MW ablation were three or fewer LR-PTCs and no recurrence beyond the neck, with ineligibility or refusal to undergo surgery. MW ablation was carried out using a 16-gauge MW antenna under local anaesthesia. Patients were then followed at 1, 3, 6 and 12 months after treatment and every 6 months thereafter. Technical success usually meant volume reduction more than 50%. Between October 2010 to March 2013 a total of 17 patients (14 women, 3 men; average age 54.1 years) with 23 LR-PTCs, were treated with MW ablation in our department. All the LR-PTCs were technical successes with the number of treatment sessions for one tumour ranging from 1 to 4 (mean, 2.3 ± 0.9). The mean volume reduction ratio of the LR-PTCs was 1 ± 86%, 47 ± 12%, 70 ± 33%, 91 ± 14% at the 1, 3, 6 and 18 months follow-up visit respectively (all p < 0.05). All treated nodules decreased in size: 30.4% nodules (7/23) had completely disappeared, 52.2% nodules (12/23) remained as small scar-like lesions. One patient experienced transient dysphonia immediately after MW ablation. No other severe and permanent complications occurred. Although with some limitations, our preliminary results are encouraging and show MW ablation may be an alternative treatment option for the control of LR-PTCs in selected patients for whom surgery is not viable.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2015.1014433
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ultrasound therapy has been investigated for over half a century. Ultrasound can act on tissue through a variety of mechanisms, including thermal, shockwave and cavitation mechanisms, and through these can elicit different responses. Ultrasound therapy can provide a non-invasive or minimally invasive treatment option, and ultrasound technology has advanced to the point where devices can be developed to investigate a wide range of applications. This review focuses on non-cancer clinical applications of therapeutic ultrasound, with an emphasis on treatments that have recently reached clinical investigations, and preclinical research programmes that have great potential to impact patient care.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2015.1004375
  • [Show abstract] [Hide abstract]
    ABSTRACT: Focused ultrasound surgery (FUS) is a non-invasive method for tissue ablation that has the potential for complete and controlled local tumour destruction with minimal side effects. The treatment of abdominal organs such as the liver, however, requires particular technological support in order to enable a safe, efficient and effective treatment. As FUS is applied from outside the patient's body, suitable imaging methods, such as magnetic resonance imaging or diagnostic ultrasound, are needed to guide and track the procedure. To facilitate an efficient FUS procedure in the liver, the organ motion during breathing and the partial occlusion by the rib cage need to be taken into account in real time, demanding a continuous patient-specific adaptation of the treatment configuration. Modelling the patient's respiratory motion and combining this with tracking data improves the accuracy of motion predictions. Modelling and simulation of the FUS effects within the body allows the use of treatment planning and has the potential to be used within therapy to increase knowledge about the patient status. This article describes integrated model-based software for patient-specific modelling and prediction for FUS treatments of moving abdominal organs.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2014.1002817
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a need for a coherent set of exposure and dose quantities to describe ultrasound fields in media other than water (including tissue and tissue-simulating materials). This paper proposes an outline dosimetry scheme, with quantities for free field exposure, in situ exposure, dose (both instantaneous and cumulative) and effect, to act as a structure for organising a more complete set of definitions. It also presents findings from a survey of the views of the therapeutic ultrasound community which generally supports the principle of using modified free field quantities to describe the in situ field, and the prioritising of dose quantities which are related to heating and thermal mechanisms. Although there is no one-to-one relationship between any known ultrasound dose quantity and a specific biological effect, this can also be said of radiotherapy and other modalities where weighting factors have been developed to calculate the degree of equivalence between different tissues and radiation types. This same separation is recommended for ultrasound, provided that an appropriate set of recognised 'engineering' quantities can be established for exposure and dose quantities.
    International Journal of Hyperthermia 03/2015; 31(2):182-192. DOI:10.3109/02656736.2014.997311
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical efficacy of thrombolytic drugs is limited by lack of specific delivery and requires large therapeutic doses which increase toxicity. Encapsulating these drugs in temperature-sensitive liposomes and applying hyperthermia to deliver thrombolytic agents locally to thrombus might theoretically favourably alter the therapeutic window. The objectives of this study were to formulate liposomes encapsulating thrombolytics and assess thrombolytic activity following hyperthermia. Three liposome formulations were investigated: temperature-sensitive liposome (TSL, DPPC:DSPE-PEG2000 (mol% 95:5)), low temperature-sensitive liposome (LTSL, DPPC:MSPC:DSPE-PEG2000 (mol% 85.3:9.7:5)), and traditional temperature-sensitive liposome (TTSL, DPPC:HSPC:Chol:DSPE-PEG2000 (mol% 55:25:15:5)). To characterise temperature-dependent release of high molecular weight cargo from each formulation, fluorescein-conjugated dextrans (70 kDa) were loaded and release was quantified via spectrophotometry. Staphylokinase (SAK), urokinase, and tissue-type plasminogen activator were also loaded individually into each liposome formulation. Leakage at 37 °C and release at 38-44 °C were quantified via chromogenic enzymatic activity assay. Clot lysis was evaluated by measuring mass of blood clots before and after thrombolytic liposome treatment. The LTSL formulation had optimal release characteristics with maximum release at 41.3 °C. Release of dextrans from LTSLs was observed to be 11.5 ± 1.5%, 79.7 ± 1.6%, and 93.6 ± 3.7% after 15 min in plasma at 37°, 39°, and 41.3 °C, respectively. The SAK LTSL had the highest release/leakage ratio and demonstrated greater clot lysis. The SAK LTSL achieves significant clot lysis in vitro. When combined with local hyperthermia, the SAK LTSL potentially produces sufficient thrombolysis while minimising systemic side effects.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2014.991428
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study sought to evaluate the safety and efficacy of ultrasound-guided (US-guided) percutaneous microwave (MW) ablation combined with percutaneous ethanol injection (PEI) to treat liver tumours adjacent to the gallbladder. A total of 136 patients with hepatocellular carcinoma (HCC) adjacent to the gallbladder, who underwent ultra-sonographically-guided percutaneous MW ablation, which was combined with PEI in132 patients, were retrospectively assessed. The patient population characteristics, tumour features, local tumour progression and treatment were compared and analysed. The safety and efficacy of the therapy were assessed by clinical data and imaging in follow-up examinations. All patients were completely treated with two sessions; 120 patients underwent one session, 16 patients underwent two sessions. The primary technique was effective in 95.6% of the cases, according to the computed tomography (CT) or magnetic resonance imaging (MRI) in the one-month follow-up (132 of 138 sessions). PEI and other therapies were performed in the patients who had been incompletely treated (all six patients underwent PEI, and some underwent other therapies, including one transcatheter arterial chemoembolisation (TACE), one liver transplantation and two liver resections). There was a median follow-up period of 30.1 months and a range of 4 to 68 months. None of the patients had major complications. There were no treatment-related deaths. Twenty-six patients died of primary disease progression that was not directly attributable to MW ablation (19.1%, 26/136). Local tumour progression was noted in five patients (3.7%, 5/136), who had completely ablated tumours at follow-up. The patients with locally progressing tumours underwent additional therapy (three patients underwent PEI, one patient TACE, and one liver resection). Ultrasound-guided percutaneous MW ablation, in combination with percutaneous ethanol injection and thermal monitoring, is a safe and effective treatment for HCC adjacent to the gallbladder.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2014.999017
  • International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2015.1011716
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the safety and effectiveness of contrast-enhanced ultrasound (CEUS) on ultrasound guided high intensity focused ultrasound (USgHIFU) ablation of uterine fibroids. Thirty-three patients (37 fibroids) were randomly assigned to two groups: group A (17 patients, 20 fibroids) in which CEUS was used before, during and after HIFU treatment, and group B (16 patients, 17 fibroids) in which CEUS was not administered at all. Follow-up including contrast-enhanced magnetic resonance imaging (MRI) and a clinical questionnaire was performed, and technical success, ablation efficacy, volume reduction and complications were assessed. Technical success was 100% in both groups. CEUS revealed residual enhancement in 40% of the patients in group A and the treatment was continued until the completion of ablation. MRI at 1 month after treatment revealed significant difference in the relative fibroid volume reduction rate between the two groups: 16.1% in group A versus 4.8%, in group B (p = 0.01). There was no statistically significant relative volume reduction rate for the results at 3, 6 and 12 months and no significant changes in the quality of life results or the complication rate. CEUS was safe and effective in enhancing US guidance during HIFU ablation of uterine fibroids. Moreover, the use of CEUS during HIFU sonication increased the ablation efficacy, leading to a more relevant fibroid volume reduction at 1 and 3 months. This gap disappeared after 6 months, when there were no differences between the two groups of patients at MRI. However, in our experience, USgHIFU represented a very effective method for the treatment of uterine fibroids, and the use of CEUS during HIFU procedure reduced the treatment time and treatment repetitions for incomplete fibroid ablation.
    International Journal of Hyperthermia 03/2015; DOI:10.3109/02656736.2015.1004134